Waldencast plc (WALD) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with significant revenue and profit growth, despite challenges in the competitive and economic landscape. Management's confidence in innovation and market strategy, particularly with new product launches, suggests positive future prospects. The new credit facility enhances financial flexibility, and the shareholder return plan remains stable. Although there are concerns about regulatory expenses and supply chain issues, the overall sentiment is positive, likely leading to a stock price increase.
Key Financial Performance
Net Revenue (Q4 2024) $72.1 million, a 29.4% increase year-over-year, driven by balanced performance across brands, with Milk Makeup growing 31.9% and Obagi Medical growing 27.7%.
Adjusted Gross Profit (Q4 2024) $52.6 million, a 30.7% increase from $40.3 million in Q4 2023, with adjusted gross profit margin stable at 73%.
Adjusted EBITDA (Q4 2024) $11.2 million, doubled from Q4 2023, with an adjusted EBITDA margin expansion of 530 basis points to 15.5%, reflecting strong revenue momentum and improved operational leverage.
Net Revenue (Fiscal Year 2024) $273.9 million, a 27.5% increase year-over-year.
Adjusted Gross Profit (Fiscal Year 2024) $203.6 million, a 35.3% increase from 2023, with adjusted gross profit margin of 74.3%, a 530 basis point improvement year-over-year.
Adjusted EBITDA (Fiscal Year 2024) $40.3 million, a 65.1% increase from fiscal 2023, with adjusted EBITDA margin expanding to 14.7%, a 350 basis point increase from 11.2% in 2023.
Adjusted EBITDA to Cash Conversion Ratio (Fiscal Year 2024) 78.8%, achieved through effective working capital management.
Cash Position (End of 2024) $14.8 million, with an additional $30 million available on the revolving credit facility.
Net Debt (End of 2024) $154.2 million.
Shares Outstanding (as of February 28, 2025) 122.7 million shares.
New Credit Facility Secured a new $205 million five-year credit facility, providing greater financial flexibility and extending debt maturity profile through 2030.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Milk Makeup introduced Jelly skincare, the first jelly serum stick, and Hydro Grip Gel Tint, a long-lasting skin tint, both aimed at expanding their product offerings.
Brand Expansion: Milk Makeup expanded its distribution by launching in over 600 Ulta Beauty locations, enhancing its market presence.
Innovation: Obagi Medical launched new products including the Super Antioxidant Serum and Moisture Restore Hydration Replenishing Cream, targeting consumer needs.
Market Positioning: Milk Makeup is growing five times faster than the overall beauty market, while Obagi Medical is the fastest growing among the top 10 professional skincare brands in the U.S.
Operational Efficiency: Adjusted EBITDA margin expanded to 14.7%, reflecting improved operational leverage despite increased investments.
Cash Conversion: Achieved an adjusted EBITDA to cash conversion ratio of 78.8%, indicating effective working capital management.
Strategic Growth Initiatives: Waldencast aims to build a multi-brand platform encompassing key categories and geographies, leveraging the Waldencast Flywheel Effect for growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Investigation: A significant portion of the company's cash is currently being used to cover non-recurring expenses associated with an ongoing regulatory investigation, which may impact cash generation until resolved.
Competitive Pressures: The beauty market is experiencing competitive pressures, with the company needing to maintain its growth rate and market share against top competitors.
Supply Chain Challenges: There are indications of inventory adjustments among retail partners, which could affect revenue growth in the short term.
Economic Factors: The company operates in an uneven consumer market, which poses risks to sustained growth despite the overall resilience of the beauty industry.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Growth Initiatives: Waldencast is focused on building a global beauty and wellness platform that creates, acquires, accelerates, and scales high-growth, purpose-driven brands. The company aims to expand its multi-brand platform across key categories, geographies, channels, and price points.
Milk Makeup Growth Strategy: Milk Makeup's growth strategy includes expanding brand awareness, launching market-disrupting beauty innovations, and broadening its footprint in both online and offline channels.
Obagi Medical Growth Strategy: Obagi Medical's strategy focuses on enhancing brand identity, driving science-backed innovation, and increasing brand awareness and footprint to fuel its physician-centered ecosystem.
Fiscal 2025 Revenue Growth: Waldencast anticipates net revenue growth in the mid-teens for fiscal 2025.
Adjusted EBITDA Margin Outlook: The company expects adjusted EBITDA margin to expand into the mid to high teens in fiscal 2025.
Q1 2025 Revenue Expectations: Net revenue for Q1 2025 is expected to be relatively flat due to inventory adjustments and the timing of product launches.
Long-term Financial Position: Waldencast expects to improve cash generation following the resolution of ongoing regulatory investigations, enhancing its financial position and capital structure.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Count: As of February 28, 2025, there were 122.7 million shares outstanding.
Credit Facility: Secured a new $205 million five-year credit facility, which includes a $175 million term loan and a $30 million revolving credit facility.
Net Debt: Net debt totaled $154.2 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you kind of give us some details on the cadence of innovation and what gives you the confidence that you can get sales to accelerate through the year?
A:Our guidance is clear, and we are confident in growth on both fronts with a clear acceleration. Q1 is affected by the anniversary of jellies and retail inventory adjustments. We expect strong acceleration throughout the year with new innovations like Skin Tint and the Ulta launch.
Q:Are you able to quantify the boost that jellies gave in the first quarter?
A:We don't disclose specific numbers for competitive reasons, but jellies accounted for the majority of the difference in Q1.
Q:What might be different from last year in your marketing spend?
A:We expect to accelerate our marketing investment, especially for Milk, which is evolving to include broader paid brand campaigns alongside influencer marketing.
Q:Are you seeing any sort of softness in the physician dispense channel?
A:The DTP channel continues to perform strongly, albeit normalizing a bit, but remains robust with trends supporting our business.
Q:Can you talk a little bit about the macro environment and consumer health you have embedded for the guide for the year?
A:The beauty consumer remains resilient, with premium beauty performing ahead of mass. Our growth prospects are relatively independent of market variations.
Q:Can you help us on Q1? How much of the flat year-over-year is due to growth deceleration versus retail inventory correction?
A:The deceleration is mainly due to the anniversary of jellies and retail inventory adjustments, but we are confident in acceleration throughout the year.
Q:Is there the potential to go beyond 600 doors if the Ulta launch is successful?
A:Yes, there is potential, but we are focused on limiting distribution to ensure high productivity per store.
Q:Do you have an operating cash flow and a capital spending number for 2024?
A:You will have the full financials in the 20th report.
Q:Was all the sell-in for Ulta in the December quarter, or did any of that trickle into the March quarter?
A:Part was shipped in Q4, and part has been shipped in Q1.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers regarding the boost from jellies in Q1 and the operating cash flow and capital spending numbers for 2024.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alec Legg
Beauty brand
Canaccord Genuity
Cult Gen
Davidson Olivia
Flywheel Effect
Milk Obagi
Obagi Medical
Obagi brand
Prestige Beauty
Skincare
Ulta Beauty
Waldencast Flywheel
average
brand Milk
brand product
brand strength
capability momentum
capital
category Prestige
credit facility
dividend
driver investment
driver line
expertise
group capability
highlight increase
leverage
market beauty
pleasure
point improvement
power brand
rate
release yesterday
skincare brand
time
today brand
WALD Transcript
Waldencast plc (WALD) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed picture: strong cost management and improved margins are positive, but declining revenues, increased net debt, and challenges in international sales for Milk Makeup are concerning. The Q&A highlighted operational disruptions and unclear management responses. While optimistic guidance and strategic growth initiatives could support future growth, the current financials and uncertainties balance the overall sentiment to neutral.
Waldencast plc (WALD) Q4 2024 Earnings Call Transcript
Neutral3-19
Waldencast plc (WALD) Q4 2024 Earnings Call Transcript
Positive3-19
The earnings call reflects strong financial performance with significant revenue and profit growth, despite challenges in the competitive and economic landscape. Management's confidence in innovation and market strategy, particularly with new product launches, suggests positive future prospects. The new credit facility enhances financial flexibility, and the shareholder return plan remains stable. Although there are concerns about regulatory expenses and supply chain issues, the overall sentiment is positive, likely leading to a stock price increase.
Waldencast plc. (WALD) Q3 2024 Earnings Call Transcript
Positive11-23
The earnings call presents strong financial performance with significant revenue and EBITDA growth for both Milk Makeup and Obagi Medical. Despite a slight decline in Milk Makeup's gross margin, the overall financial health is robust, supported by improved operational efficiencies. The Q&A highlights optimism in innovation and minimal tariff impact, with plans to manage gross margins effectively. While management avoided specific details on brand awareness, the overall sentiment remains positive due to strong growth metrics and strategic initiatives, suggesting a likely positive stock price movement in the short term.
WALD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
